3月 17, 2021 | 未分类
SAN DIEGO, Calif., March 17, 2021 – Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced that the U.S. Food and...
2月 23, 2021 | 未分类
SAN DIEGO, Calif., February 23, 2021 – Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet...
1月 4, 2021 | 未分类
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Ambrx announced that the U.S. Food and Drug Administration (FDA) granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or...
12月 10, 2020 | 未分类
• 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU
• Multiple Global Phase...
11月 9, 2020 | 未分类
SAN DIEGO, November 9, 2020 – Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced today the successful closing of an oversubscribed...
